This presents unique opportunities to repurpose FDA-approved compounds that target neuron-produced mitogens (e.g., collagenase75) or HCN channels (e.g., Lamotrigine; Ivabradine76,77) for the treatment of NF1-associated nervous system tumors, expanding the toolbox for targeting neuron-low-grade tumor interactions in cancer. This evidence concerns the gene NF1 and cancer.